Chronic alpha1-adrenergic blockade improves hypertension and renal injury in L-NAME and low-renin L-NAME-DOCA hypertensive rats

Medical Science Monitor

Volumn 8, Issue 9, 2002, Pages

  Wangensteen, Rosemary ^a   O'Valle, Francisco ^a   Del Moral, Raimundo G ^a   Vargas, Félix ^a   Osuna, Antonio ^a  

^a UNIVERSITY OF GRANADA   (Spain)

Author keywords

Adrenergic antagonist; Deoxycorticosterone; Experimental hypertension; L NAME; Renal disease

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; CREATININE; DEOXYCORTICOSTERONE ACETATE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PRAZOSIN; UREA; DEOXYCORTICOSTERONE; ENZYME INHIBITOR; RENIN;

ADRENERGIC ACTIVITY; ALPHA ADRENERGIC RECEPTOR BLOCKING; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; HEART HYPERTROPHY; HYPERTENSION; KIDNEY HYPERTROPHY; KIDNEY INJURY; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PROTEINURIA; RAT; SYSTOLIC BLOOD PRESSURE; UREA BLOOD LEVEL; ANIMAL; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; GLOMERULUS; INJURY; KIDNEY; KIDNEY DISEASE; METABOLISM; PATHOLOGY; RENOVASCULAR HYPERTENSION; TIME; WISTAR RAT;

ANIMALS; DESOXYCORTICOSTERONE; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; HYPERTENSION, RENAL; KIDNEY; KIDNEY DISEASES; KIDNEY GLOMERULUS; MALE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; RATS; RATS, WISTAR; RECEPTORS, ADRENERGIC, ALPHA-1; RENIN; TIME FACTORS;

EID: 0036730323     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Baylis G, Mitruka B, Deng A: Chnmic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest, 1992; 90: 278-81
2. Sander M, Victor RG: Neural mechanisms in nitric-oxide-deficient hypertension. Curr Opin Nephrol Hypertens, 1999; 8: 61-73
3. Baron AD, Zhu JS, Marshall S, Irsula O, Brechtel G, Keech C: Insulin resistance after hypertension induced by the nitric oxide synthesis inhibitor L-NMMA in rats. Am J Physiol, 1995; 209: E709-15
4. Lacolley PJ, Lewis SJ, Brody MJ: Role of sympathetic nerve activity in the generation of vascular nitric oxide in urethane-anesthetized rats. Hypertension, 1991; 17: 881-7
5. Pucci ML, Lin L, Nasjletti A: Pressor and renal vasoconstrictor effects of N‴-nitro-L-arginine as affected by blockade of pressor mechanisms mediated by the sympathetic nervous system, angiotensin, prostanoids mtd vasopressin. J Pharm Exp Ther, 1992; 261: 240-5
6. Manning RD, Hu L, Williamson, TD: Mechanisms involved in the cardiovascular-renal actions of nitric oxide inhibition. Hypertension, 1994; 23 [part 2]: 951-6
7. Zanchi A, Schaad NC, Osterheld MC et al: Effects of chronic NO synthase inhibition in rats on renin-angiotensin system and sympathetic nervous system. Am J Physiol, 1995; 268: H2267-73
8. Qiu C, Engels K, Baylis C: Angiotensin 11 and alpha 1-adrenergic tone in chronic nitric oxide blockade-induced hypertension. Am J Physiol, 1994; 266: R1470-6
9. Scrogin KE, Hatton DC, Chi Y, Luft FC: Chronic nitric oxide inhibition with L-NAME: Effects on autonomic control of the cardiovascular system. Am J Physiol, 1998; 274: R307-74
10. Sander M, Hansen J, Victor RG: The sympathetic nervous system is involved in the maintenance but not initiation of the hypertension induced by N‴-nitro-L-arginine methyl ester. Hypertension, 1997; 30 [part 1]: 64-70
11. Álvarez G, Osuna A, Wangensteen R, Vargas F: Interaction between nitric oxide and mineralocorticoids in the long-term control of blood pressure. Hypertension, 2000; 35: 752-7
12. De Gracia MC, Osuna A, O'Valle F et al: Decoxycorticosterone suppresses the effects of losartan in nitric oxide-deficient hypertensive rats. J Am Soc Nephrol, 2000; 11: 1995-2000
13. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem, 1976; 72: 248-54
14. Fitzgerald SM, Brands MW: Hypertension in L-NAME-treated diabetic rats depends on au intact sympathetic nervous system. Am J Physiol, 2002; 282(4); R1070-6
15. Fulgenzi G, Graciotti L, Collis MG, Hudlická O: The effect of alpha 1 adrenoceptor antagonist prazosin on capillary supply, blood flow and performance in a rat model of chronic muscle ischaemia. Eur J Vasc Endovasc Surg, 1998; 16: 71-7
16. Aizawa T, Ishizaka N, Usui S-I, Ohashi N, Ohano M, Nagai R: Angiotensin 11 and catecholamines increase plasma levels of 8-epiprostaglandin F2α with different pressor dependencies in rats. Hypertension, 2002; 39: 149-54
17. Sánchez A, Sáiz J, Torres A, Montero D, Martínez-Sierra R: Effects of prazosin and yohimbine on systolic blood pressure and on renal norepinephrine content in DOCA-salt rats. Life Sci, 1985; 36: 1589-96
18. Dworkin LD, Feiner HD, Randazzo J: Glomerular hypertension and injury in desoxycorticosterone-salt rats on antihypertensive therapy. Kidney Int, 1987; 31: 718-24
19. Hill GS, Heptinstall RH: Steroid-induced hypertension in the rat. Am J Pathol, 1968; 52: 1-20
20. Kim S, Ohta K, Hamaguchi A et al: Role of angiotensin 11 in renal injury of deoxycorticosterone acetate-salt hypertensive rats. Hypertension, 1994; 24: 195-204
21. Border WA, Noble NA: Interactions of transforming growth factor-beta and angiotensin 11 in renal fibrosis. Hypertension, 1998; 31 [part 2]: 181-8
22. Pollock DM, Polakowski JS, Divish BJ, Opgenorth TJ: Angiotensin blockade reverses hypertension during long-term nitric oxide synthase inhibition. Hypertension, 1993; 21: 660-6
23. Fernández-Rivas A, García-Estań J, Vargas F: Effects of chronic increased salt intake on nitric oxide synthesis inhibition-induced hypertension. J Hypertens, 1995; 13: 123-8
24. Lee RMKW, Richardson M, McKenzie R: Vascular changes associated with deoxycorticosterone-NaCI-induced hypertension. Blood Vessels, 1989; 26: 137-56
25. Young M, Fullerton M, Dilley R, Funder J: Mineralocorticoids, hypertension and cardiac fibrosis. J Clin Invest, 1994; 93, 2578-83